Publication | Closed Access

SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial

Hematological MalignancyLymphoid NeoplasiaMedicineMalignant Blood DisorderImmunologyPathologyEzh2 InhibitorAdult T-cell Leukemia-lymphomaImmunotherapyOncologyRadiation OncologyCancer Research